Effect of levodopa-carbidopa intestinal gel on dyskinesia: Design of an open-label, randomized multicenter 12-week study in advanced Parkinson’s disease patients
Objective: To examine the effect of levodopa-carbidopa intestinal gel (LCIG, designated carbidopa-levodopa enteral suspension in the US) treatment relative to that of optimized medical treatment…Sleep quality in patients with advanced Parkinson’s disease treated with levodopa/carbidopa intestinal gel infusion
Objective: To describe the effects of levodopa/carbidopa intestinal gel (LCIG) infusion on sleep quality in patients with advanced Parkinson's disease (PD). Background: Worsening of sleep…How Usual Is Skin Rashes During Treatment With Levodopa / Benserazide Hydrochloride?
Objective: To clarify the possible associations of levodopa / benserazidehydrochloride usage and skin rashes. Background: Levodopa/benserazide hydrochloride is one of the best dopaminergic drug used…Wearing Off Frequency in Different Hoehn-Yahr Stages in Parkinson’s Disease
Objective: To determine wearing off frequency in different stages of Parkinson’s disease (PD). Background: Levodopa is the gold standard in the symptomatic treatment of PD. The…Long-term levodopa therapy accelerates the circadian rhythm dysfunction in 6-OHDA rat model
Objective: We aimed to study the effect of L-DOPA on circadian rhythms in 6-OHDA lesioned rats, and to clarify whether the disturbance of the circadian…A novel cause for unpredictable response to levodopa
Objective: [To describe a novel cause for unpredictable response to levodopa] Background: A fluctuating response to levodopa is common in advanced Parkinson’s disease and can…Automated dosing schemes for administration of microtablets of levodopa for Parkinson’s disease, using wearable sensors
Objective: The aim of this study is to investigate the feasibility of using a dose optimization algorithm for dose individualization of microtables of levodopa. Background:…Speech and voice response to levodopa in late-stage Parkinson’s Disease patients: report from an acute levodopa challenge
Objective: to assess the change of speech and voice after an acute L-dopa challenge in late-stage Parkinson’s disease (LSPD). Background: PD patients are classically affected…Treatment of secondary movement disorders related to midbrain cavernomas
Objective: To evaluate possible efficacy and safety of standard antiparkinsonian drugs (levodopa formulations, amantadine) in patients with symptomatic midbrain cavernomas (haemorhage and/or surgery) and secondary…Levodopa effect and motor function in late stage Parkinson’s disease
Objective: To assess responsiveness to Levodopa (L-dopa) in patients with late stage Parkinson’s disease (PD). Moreover, to investigate if the L-dopa effect is stable or…
- « Previous Page
- 1
- …
- 49
- 50
- 51
- 52
- 53
- …
- 62
- Next Page »